Viewing
News|Articles|November 19, 2026

Neurolens N3 gains CE mark under EU MDR for ocular misalignment

Neurolens N3 measurement system and HIT-6 trial data

Newton has received CE marking under the EU Medical Device Regulation (EU MDR) for the Neurolens N3 (Newton), according to a new announcement. The eye-tracking system measures ocular alignment to guide contoured prism lens prescriptions for symptoms linked to ocular misalignment. Intertek Medical Notified Body AB issued the certification, which clears the N3 for commercialisation across the European Union and European Economic Area.1

The Dallas, Texas-based company expects to introduce Neurolens in its first European markets in 2027, extending the technology beyond the United States and Canada. According to the company, eye care professionals in 30 European countries will be able to offer the lenses. Newton positions Neurolens as a non-pharmaceutical option for headaches, neck and shoulder pain, and motion sickness associated with ocular misalignment.1

The N3 is a headset-based device measuring ocular alignment objectively at distance and near using eye-tracking. According to Newton, the automated test takes a few minutes, can be run by trained staff and produces output translating directly into a Neurolens Contoured Prism prescription. Newton reports more than 4 million eye alignment measurements and more than 350,000 patients helped by Neurolens technology across North America.1

In its announcement, Newton cites a randomised, double-masked, crossover trial (NCT05070767) published in Translational Vision Science & Technology in 2024.1 The study enrolled adults aged 18 to 60 years with a Headache Impact Test-6 (HIT-6) score of 56 or higher at 10 US optometry practices, and 170 of 195 randomised participants (88%) completed all visits. Participants wore Neurolens lenses and prism-free control lenses (Shamir Autograph II) in sequence for 30 ± 10 days each, with no washout period.2

Newton reports an average 5-point reduction in HIT-6 scores after 4 weeks of wear.1 In the peer-reviewed analysis, the mean between-treatment difference in HIT-6 score favoured Neurolens over control by −1.53 points (95% CI, −2.8 to −0.26; P = .018). A sensitivity analysis using multiple imputation produced a similar difference of −1.48 points (95% CI, −2.84 to −0.12; P = .033).2

Frequently Asked Questions

What is the Neurolens N3?

The Neurolens N3 is a headset-based eye-tracking system from Newton measuring ocular alignment at distance and near. Its output is used to prescribe Neurolens spectacle lenses with Contoured Prism technology.

What does the CE mark under EU MDR allow?

The certification clears the N3 for commercialisation across the European Union and European Economic Area. Newton expects to launch Neurolens in its first European markets in 2027.

What did the Neurolens headache trial show?

In a randomised, double-masked crossover trial, Neurolens reduced HIT-6 scores by 1.53 points more than prism-free control lenses (P = .018). The authors describe the difference as statistically significant but below the threshold for clinical significance.

Neurolens subgroup results, safety and study limitations

In a subgroup of 98 participants with a reduced near point of convergence (greater than 5 cm), the HIT-6 difference of −1.89 points did not reach statistical significance (P = .116). The study authors cite a 2.5-point threshold for a clinically meaningful change and state the overall reduction was not clinically significant, although a clinically meaningful benefit could not be ruled out with high certainty.2 Separately, Newton reports 90% of wearers surveyed after 60 days described symptom improvement.1

The authors reported 2 anticipated adverse events, one in each lens arm, in which participants could not adapt to or wear the study lenses. The paper does not include a formal safety analysis.2

Neurolens Inc funded the trial, and 4 company-affiliated authors, 2 holding management positions and equity, were involved in its design. The investigators did not monitor compliance with lens wear, and 112 participants wore Neurolens first while 83 wore control lenses first. The authors suggest clinicians evaluate vision-related disorders in patients strongly affected by headaches or digital eye strain, even when existing binocular vision diagnostic criteria are not met.2

Davis Corley, chief executive officer of Newton, described the certification as "a defining milestone for Newton" and said it opens the door for eye care professionals across Europe. Gregory Boisse, senior vice president of operations and research and development at Newton, said the certification "represents years of collaboration and a shared commitment to patient safety, product quality, and continuous improvement."1

In its announcement, Newton cites Eurolight survey data from more than 8,000 adults in 9 European countries, in which nearly 4 in 5 reported a headache in the previous year.1,3 The company's portfolio also includes Sequel, a lens with Convergence Boost technology for digital eye strain, and the Newton Vision Care Platform.1

References
1. Newton. Newton's Neurolens N3 receives CE mark under EU MDR. PR Newswire. Published 17 November 2026. Accessed 18 November 2026. https://www.prnewswire.com/news-releases/newtons-neurolens-n3-receives-ce-mark-under-eu-mdr-302941457.html
2. Labhishetty V, Cortes J, van de Pol C, et al. Impact of Neurolens use on the quality of life in individuals with headaches: a randomized double-masked, cross-over clinical trial. Transl Vis Sci Technol. 2024;13(1):27. doi:10.1167/tvst.13.1.27
3. Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15(1):31. doi:10.1186/1129-2377-15-31

Related to this article